LEAD SERIES DEVELOPMENT & OPTIMISATION OF A NEW DRUG AGAINST ACTIVE AND LATENT TUBERCULOSIS

根据最新的估计，2009年结核病导致170万人死亡(大约每20秒就有一人死亡)。结核病的治疗依赖于大约40年前开发的药物。不幸的是，这些药物不是很好，因为它们需要长期的治疗方案(6-9个月)，而且往往由于结核病细菌产生抗药性的能力而不起作用。使用一种新的策略，我们提议开发一种新药，能够迅速杀死所有结核病细菌，包括耐药的结核病细菌。为了开发这种药物，我们已经与业界(葛兰素史克制药)合作，并将使用类似行业的开发和管理方法。如果我们在这个为期两年的项目中取得成功，我们有信心从结核病联盟获得未来的资金，以便我们最终能够在未来五到六年内注册我们的新药。

According to the most recent estimates, TB killed 1.7 million people in 2009 (approximately a death every 20seconds). Treatment for TB relies on drugs developed some 40 years ago. Unfortunately these drugs are not very good as they require long treatment regimes (6-9 months) and often they do not work due to the ability of the TB bug to develop resistance. Using a novel strategy we propose to develop a new drug that will be able to kill all of the TB bugs quickly including the resistant ones. To develop this drug we have partnered up with industry (GSK pharmaceuticals) and will use industry-like development and management methods. If we succeed in this 2 year project, we are confident that we can secure future funding from the TB Alliance so that we can eventually register our new drug within the next five or six years.